Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296703 | 1.00 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL30296712 | 0.89 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL26620185 | 0.89 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL26620114 | 0.78 | SMN1; SMN2 (0.34) | NPC1 | |
| SCHEMBL30296745 | 0.78 | SMN1; SMN2 (0.34) | NPC1 | |
| SCHEMBL31275214 | 0.73 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL31274136 | 0.73 | MAPT (0.35) | DGAT1NPC1 | |
| SCHEMBL30296721 | 0.72 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL26620126 | 0.72 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL30903068 | 0.70 | KCNJ5 (0.39) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-08-15 | — | — | US | disclosed |
| US-11939344-B2 | Spirocyclic compounds | ASTRAZENECA AB (SE) | 2024-03-26 | — | — | US | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | DGAT1 2739/4885NPC1 224/4885 |
| US-11939344-B2 | Spirocyclic compounds | PKD1, PKD2, NR5A1 | DGAT1 2535/4885NPC1 228/4885 |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | DGAT1 2739/4885NPC1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.